Drug efficacy evaluation study for fibrotic diseases involving multiple organs
We want to introduce a paper by Insilico Medicine, a company that focuses on fibrosis to develop drugs, and after conducting pre-clinical studies in mice at our company, submitted the results of their research to Nature Biotechnology.
Ren et al., Nat Biotechnol., 2024
This article identifies TRAF2- and NCK-interacting kinase (TNIK) as an anti-fibrotic target using AI and describes the results of pre-clinical and clinical trials in animal models of lung, skin and kidney fibrosis.
It has been observed that the same compound shows its therapeutic effect on fibrosis across multiple organs as described above.
In the past, some companies have evaluated the same compound across multiple organs, such as the liver, lungs, kidneys, intestines and skin, in the development of fibrosis-related therapeutics and have proceeded with the development for diseases that showed particularly promising results.
We believe, the reason that we receive requests like the one mentioned above, is due to our experience and track record of conducting studies with more than 1,000 companies focusing particularly on the pathological evaluation of inflammatory and fibrotic diseases.
Due to our wealth of experience in conducting various preclinical drug evaluation studies in the field of inflammation and fibrosis over the past 20 years, we are confident to propose the best study design for your needs in order to accelerate your compound development.
If you are interested, please feel free to contact us.